natgillin/translations-raw huggingface dataset:
Do not take Olanzapine Teva: - if you are allergic to olanzapine or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na olanzapin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
- Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. 
- Zelo redko tovrstna zdravila povzročijo kombinacijo zvišanja telesne temperature, pospešenega dihanja, znojenja, okorelosti mišic in dremavosti ali zaspanosti.
Other medicines and Olanzapine Teva 
Druga zdravila in zdravilo Olanzapin Teva
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5HT than D activity in vivo models. 
V pogojih in vitro je olanzapin pokazal večjo afiniteto za serotoninske 5-HT2 kot za dopaminske D2 receptorje in večjo 5-HT kot D aktivnost v modelih in vivo.
What Olanzapine Teva is and what it is used for 
Kaj je zdravilo Olanzapin Teva in za kaj ga uporabljamo
Tardive dyskinesia11 Amnesia9 
Tardivne diskinezije11 Amnezija9
Olanzapine Teva has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment. 
Zdravilo Olanzapin Teva dokazano preprečuje ponoven pojav teh simptomov pri bolnikih z bipolarno motnjo, pri katerih se je manična epizoda po zdravljenju z olanzapinom izboljšala.
A small study of the effect of impaired liver function in 6 subjects with clinically significant (Childs Pugh Classification A (n = 5) and B (n = 1)) cirrhosis revealed little effect on the pharmacokinetics of orally administered olanzapine (2.5 - 7.5 mg single dose): Subjects with mild to moderate hepatic dysfunction had slightly increased systemic clearance and faster elimination half-time compared to subjects with no hepatic dysfunction (n = 3). 
Majhna študija učinka okvarjene funkcije jeter pri 6 preiskovancih s klinično značilno cirozo (Childs Pugh klasifikacija A (n = 5) in B (n = 1)) je pokazala majhen učinek na farmakokinetiko peroralno apliciranega olanzapina (2,5-7,5 mg enojni odmerek): osebe z blago do zmerno jetrno okvaro so imele nekoliko povišan sistemski očistek in hitrejši razpolovni čas izločanja v primerjavi s preiskovanci brez jetrne okvare (n = 3).
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines. 
Pri bolnikih s zvišano ALT in/ali AST, bolnikih z znaki in simptomi okvarjenega delovanja jeter, bolnikih s prej obstoječimi stanji, povezanimi z omejeno jetrno funkcionalno rezervo, in pri bolnikih, ki se zdravijo s potencialno hepatotoksičnimi zdravili, je potrebna previdnost in nadaljnje spremljanje.
Dystonia (including oculogyration)11 
(vključno z okulogiracijo)11
If you take more Olanzapine Teva than you should Patients who have taken more Olanzapine Teva than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. 
Bolniki, ki so vzeli večji odmerek zdravila Olanzapin Teva, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
In addition, the 15 mg strength contains indigo carmine (E132) and the 20 mg strength contains iron oxide red (E172). 
15 mg oblika zdravila poleg tega vsebuje še indigo karmin (E132), 20 mg oblika pa rdeč železov oksid (E172)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 12. 
Datum prve odobritve: 12. december 2007 Datum zadnjega podaljšanja: 12 december 2012
Ventricular tachycardia/fibrill ation, sudden death (see section 4.4)11 
Prekatna tahikardija/fibrilacij a, nenadna smrt (glejte poglavje 4.4)11
Children and adolescents Olanzapine Teva is not for patients who are under 18 years. 
Zdravilo Olanzapin Teva ni namenjeno bolnikom, mlajšim od 18 let.
It may be harmful for patients with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. 
Lahko škoduje bolnikom, ki imajo fenilketonurijo, redko genetsko bolezen, pri kateri pride do kopičenja fenilalanina, ker se ne more ustrezno odstranjevati iz telesa.
Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control. 
moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
Hepatitis (including hepatocellular, cholestatic or mixed liver injury) 
Hepatitis (vključno s hepatocelularno, holestatsko ali mešano okvaro jeter)11
- carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Olanzapine Teva dose. 
- zdravila za Parkinsonovo bolezen, - karbamazepin (antiepileptik in stabilizator razpoloženja), fluvoksamin (antidepresiv) ali ciprofloksacin (antibiotik) - morda bo treba spremeniti vaš odmerek zdravila Olanzapin Teva.
Development or exacerbation of 
Razvoj ali poslabšanje sladkorne bolezni,
≥500 milliseconds [msec] at any time post baseline in patients with baseline QTcF <500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo. 
[QTcF] ≥ 500 milisekund [msek] kadarkoli nad osnovno vrednostjo pri bolnikih z osnovno vrednostjo QTcF < 500 msek) pri bolnikih, zdravljenih z olanzapinom, redka (od 0,1 % do 1 %), brez pomembnih razlik v spremljajočih srčnih dogodkih v primerjavi z bolniki, zdravljenimi s placebom.
Olanzapine Teva film-coated tablets contain lactose. 
Olanzapin Teva filmsko obložene tablete vsebujejo laktozo.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu<, and on the website of {name of MS Agency (link)}>. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu< in na spletni strani {ime agencije v državi članici (povezava)}>.
6 weeks). 
65 let.
Olanzapine Teva with alcohol 
Jemanje zdravila Olanzapin Teva skupaj z alkoholom
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin value. 
8 V kliničnih preskušanjih, ki so trajala do 12 tednov, so pri 30 % bolnikov z normalno začetno vrednostjo prolaktina, ki so se zdravili z olanzepinom, ugotovili zvišanje plazemske koncentracije prolaktina nad zgornjo mejo normalne vrednosti.
You should swallow the Olanzapine Teva tablets whole with water. 
Olanzapin Teva tablete pogoltnite cele z vodo.
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks). 
Med zdravljenjem z olanzapinom v kombinaciji z litijem ali divalproeksom se je pri 17,4 % bolnikov med akutnim zdravljenjem (do 6 tednov) pojavilo povečanje telesne mase za
In female versus male subjects the mean elimination half-life was somewhat prolonged (36.7 versus 32.3 hr) and the clearance was reduced (18.9 versus 27.3 l/hr). 
Pri ženskah v primerjavi z moškimi je bil srednji razpolovni čas izločanja nekoliko podaljšan (36,7 v primerjavi z 32,3 ure) in očistek zmanjšan (18,9 v primerjavi s 27,3 l/h).
What Olanzapine Teva looks like and contents of the pack 
Izgled zdravila Olanzapin Teva in vsebina pakiranja
5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1 M5; α1 adrenergic; and histamine H1 receptors. 
V predkliničnih študijah je olanzapin pokazal razpon afinitet do receptorjev (Ki; < 100 nM) za serotonin 5-HT2A/2C, 5-HT3, 5-HT6; dopamin D1, D2, D3, D4, D5; holinergičnih muskarinskih receptorjev M1 M5; adrenergičnih α1; in histaminskih H1 receptorjev.
There is a risk of feeling drowsy when you are given Olanzapine Teva. 
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo Olanzapin Teva, počutili zaspane.
In postmarketing reports with olanzapine, the event of sudden cardiac death has been reported in patients with olanzapine. 
V postmarketinških poročilih so pri bolnikih, ki so se zdravili z olanzepinom, poročali o primerih nenadne srčne smrti.
Do not drink any alcohol if you have been given Olanzapine Teva as together with alcohol it may make you feel drowsy. 
Če ste dobili zdravilo Olanzapin Teva, ne pijte nobenega alkohola, saj lahko zdravilo Olanzapin Teva in alkohol skupaj povzročita občutek zaspanosti.
Olanzapine Teva contains lactose, sucrose and aspartame This medicine contains lactose and sucrose. 
Zdravilo Olanzapin Teva vsebuje laktozo, saharozo in aspartam
Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo-controlled clinical trials (see section 4.8). 
V kliničnih preskušanjih, kontroliranih s placebom, so pri bolnikih, zdravljenih z olanzapinom, opažali neželene spremembe lipidov (glejte poglavje 4.8).
In placebocontrolled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementiarelated psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine treated patients compared to patients treated with placebo (3.5% vs. 1.5%, respectively). 
povezano z demenco in/ali vedenjskimi motnjami (povprečna starost 78 let), je bilo 2-kratno povečanje incidence smrti pri bolnikih, zdravljenih z olanzapinom, v primerjavi z bolniki, zdravljenimi s placebom (3,5 % v primerjavi z 1,5 %).
Urinary incontinence Urinary retention Urinary hesitation11 
Urinska inkontinenca Zastajanje urina Težave z začetkom mokrenja11
SPECIAL STORAGE CONDITIONS Do not store above 25°C. 
Shranjujtepri temperaturi do 25 °C.
Excipient with known effect Each film-coated tablet contains 275.5 mg lactose. 
Pomožna snov z znanim učinkom Ena filmsko obložena tableta vsebuje 275,5 mg laktoze.
Lemon flavour [flavouring preparation(s), maltodextrin, sucrose, gum arabic (E414), glyceryl triacetate (E1518) and alpha-Tocopherol (E307)] 
saharoza, arabski gumi (E414), gliceriltriacetat (E1518) in α-tokoferol (E307)].
Lactose monohydrate Hydroxypropylcellulose Crospovidone type A Silica colloidal anhydrous Microcrystalline cellulose Magnesium stearate 
Jedro tablete laktoza monohidrat hidroksipropilceluloza krospovidon (vrsta A) brezvodni koloidni silicijev dioksid, mikrokristalna celuloza magnezijev stearat
Olanzapine Teva contains the active substance olanzapine. 
Zdravilo Olanzapin Teva vsebuje učinkovino olanzapin.
How to take Olanzapine Teva 
Kako jemati zdravilo Olanzapin Teva
If you notice any of these symptoms seek medical advice immediately; - a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness (the frequency of this side effect cannot be estimated from the available data). 
- kombinacijo zvišane telesne temperature, pospešenega dihanja, znojenja, mišične okorelosti in dremavosti ali zaspanosti (pogostnosti tega neželenega učinka iz razpoložljivih podatkov ni mogoče oceniti).
Olanzapine Teva 2.5 mg/5 mg/7.5 mg/10 mg film-coated tablets Colour mixture white (polydextrose, hypromellose, glycerol triacetate, macrogol 8000, titanium dioxide E171) 
Olanzapin Teva 2,5 mg/5 mg/7,5 mg/10 mg filmsko obložene tablete bela barvna mešanica (polidekstroza, hipromeloza, triacetin, makrogol 8000, titanov dioksid E171) Olanzapin Teva 15 mg filmsko obložene tablete modra barvna mešanica (polidekstroza, hipromeloza, triacetin, makrogol 8000, titanov dioksid E171, indigo karmin E132)
In renally impaired patients (creatinine clearance <10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr). 
Okvarjeno delovanje ledvic Pri bolnikih z okvarjenim delovanjem ledvic (očistek kreatinina < 10 ml/min) v primerjavi z zdravimi osebami ni bilo značilne razlike v srednjem razpolovnem času izločanja (37,7 v primerjavi z 32,4 ure)
Investigations Elevated plasma prolactin levels8 
Zvišane plazemske koncentracije prolaktina8
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4)11 
občasno povezane s ketoacidozo ali komo, vključno z nekaj smrtnimi primeri (glejte poglavje 4.4)
If you stop taking Olanzapine Teva 
Če ste pozabili vzeti zdravilo Olanzapin Teva
A mass balance study showed that approximately 57% of radiolabelled olanzapine appeared in urine, principally as metabolites. 
radioaktivno označenega olanzapina pojavi v urinu, predvsem v obliki metabolitov.
Each orodispersible tablet contains 142.5 mg lactose, 0.7875 mg sucrose and 6.75 mg aspartame (E951). 
Ena orodisperzibilna tableta vsebuje 142,5 mg laktoze, 0,7875 mg saharoze in 6,75 mg aspartama (E951).
13 Following short term treatment (median duration 22 days), weight gain ≥7% of baseline body weight (kg) was very common (40.6%), ≥15% of baseline body weight was common (7.1%) and 
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25 %
Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males 
Pogosti neželeni učinki (lahko prizadenejo do 1 od 10 bolnikov) vključujejo spremembe v ravneh nekaterih krvnih celic, maščob v krvnem obtoku in v začetnih obdobjih zdravljenja, začasno povišanje jetrnih encimov, zvišanja v ravni sladkorjev v krvi in urinu, zvišanja v ravni sečne kisline in kreatinfosfokinaze v krvi, večji občutek lakote, omotico, nemirnost, tresenje, nenavadne gibe (diskinezijo), zaprtje, suha usta, izpuščaj, izgubo moči, hudo utrujenost, zadrževanje vode, ki vodi v otekanje rok, gležnjev ali nog, vročino, bolečine v sklepih ter spolne disfunkcije, kot na primer zmanjšan libido pri moških in ženskah ter erektilna disfunkcija pri moških.
Signs and symptoms 
Symptoms).
4 Observed for fasting normal levels at baseline (<5.56 mmol/l) which increased to high (≥7 mmol/l). 
4 Opazovano pri osnovnih normalnih ravneh na tešče (< 5,56 mmol/l), ki so se povišale na visoke (≥ 7 mmol/l).
3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high (≥6.2 mmol/l). 
3 Opazovano pri osnovnih normalnih ravneh na tešče (< 5,17 mmol/l), ki so se povišale na visoke (≥ 6,2 mmol/l).
Each orodispersible tablet contains 190.0 mg lactose, 1.05 mg sucrose and 9.0 mg aspartame (E951). 
Ena orodisperzibilna tableta vsebuje 190,0 mg laktoze, 1,05 mg saharoze in 9,0 mg aspartama (E951).
- The other ingredients are mannitol, aspartame (E951), magnesium stearate, crospovidone type B, lactose monohydrate, hydroxypropylcellulose and lemon flavour [flavouring preparation(s), maltodextrin, sucrose, gum arabic (E414), glyceryl triacetate (E1518) and alphatocopherol (E307)]. 
- Druge sestavine so:manitol, aspartam (E951), magnezijev stearat, krospovidon tipa B, laktoza monohidrat, hidroksipropilceluloza in limonina aroma [pripravek/ki arome, maltodekstrin,
Olanzapine is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy. 
Pediatrična populacija Zaradi pomanjkanja podatkov glede varnosti in učinkovitosti, olanzapina ne priporočamo za uporabo pri otrocih in mladostnikih mlajših od 18 let.
Olanzapine Teva orodispersible tablets are for oral use. 
Olanzapin Teva obložene tablete so za peroralno uporabo.
The most frequently (seen in ≥1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema. 
Najpogosteje poročani (opažene pri ≥ 1 % bolnikov) neželeni učinki, povezani z uporabo olanzapina v kliničnih preskušanjih, so bili zaspanost, povečanje telesne mase, eozinofilija, zvišane ravni prolaktina, holesterola, glukoze in trigliceridov (glejte poglavje 4.4), glikozurija, povečan apetit, omotica, akatizija, parkinsonizem, levkopenija, nevtropenija (glejte poglavje 4.4), diskinezija,
Excipient with known effect Each film-coated tablet contains 68.9 mg lactose. 
Ena filmsko obložena tableta vsebuje 68,9 mg laktoze.
Olanzapine Teva 5 mg orodispersible tablets Olanzapine Teva 10 mg orodispersible tablets Olanzapine Teva 15 mg orodispersible tablets Olanzapine Teva 20 mg orodispersible tablets 
Olanzapin Teva 5 mg orodisperzibilne tablete Olanzapin Teva 10 mg orodisperzibilne tablete Olanzapin Teva 15 mg orodisperzibilne tablete Olanzapin Teva 20 mg orodisperzibilne tablete
5 Observed for fasting normal levels at baseline (<1.69 mmol/l) which increased to high 
Opazovano pri osnovnih normalnih ravneh na tešče (< 1,69 mmol/l), ki so se povišale na visoke
Hepatobiliary disorders Transient, asymptomatic elevations of hepatic 
Prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT,
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, 
Druge zdravstveno pomembne posledice prevelikega odmerjanja vključujejo delirij, konvulzije, komo, možen nevroleptični maligni sindrom, depresijo dihanja, aspiracijo, hipertenzijo ali hipotenzijo, motnje srčnega ritma (< 2 % primerov prevelikega odmerjanja) in kardiopulmonalni zastoj.
In particular, tell your doctor if you are taking: - medicines for Parkinson's disease. 
Še zlasti pa povejte svojemu zdravniku, če jemljete:
Tell your doctor immediately if you have: - unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue; - blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. 
- krvne strdke v venah (občasen neželeni učinek, ki lahko prizadene do 1 od 100 bolnikov), posebej v nogah (simptomi vključujejo otekanje, bolečino in rdečino na nogah), ki lahko po žilah potujejo v pljuča ter povzročijo bolečino v pljučih in težave z dihanjem.
Excipient with known effect Each film-coated tablet contains 206.7 mg lactose. 
Ena filmsko obložena tableta vsebuje 206,7 mg laktoze.
3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high 
3 Opazovano pri osnovnih normalnih ravneh na tešče (< 5,17 mmol/l), ki so se povišale na visoke
Each orodispersible tablet contains 47.5 mg lactose, 0.2625 mg sucrose and 2.25 mg aspartame (E951). 
Ena orodisperzibilna tableta vsebuje 47,5 mg laktoze, 0,2625 mg saharoze in 2,25 mg aspartama (E951).
Olanzapine Teva 5 mg, 10 mg and 15 mg orodispersible tablets are available in cartons containing 28, 30, 35, 50, 56, 70 or 98 tablets. 
Olanzapin Teva 5 mg, 10 mg in 15 mg orodisperzibilne tablete so na voljo v pakiranjih po 28, 30, 35, 50, 56, 70 ali 98 orodisperzibilnih tablet.
Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth. 
občasno povezano s ketoacidozo (ketoni v krvi in urinu) ali komo, krče, običajno povezane s krči (epileptičnimi napadi) v preteklosti, mišično okorelost ali krče (vključno z obračanjem zrkel), sindrom nemirnih nog, težave pri govoru, jecljanje, upočasnjen srčni utrip, občutljivost za sončno svetlobo, krvavitev iz nosa, trebušno distenzijo, izgubo spomina ali pozabljivost, urinsko inkontinenco, težave pri mokrenju, izgubo las, odsotnost ali zmanjšanje menstruacij ter spremembe na prsih pri moških in ženskah, kot na primer nenormalno nastajanje mleka v prsih ali nenormalna rast.
Changes in fasting glucose from borderline at baseline (≥5.56-<7 mmol/l) to high (≥7 mmol/l) were very common. 
Zelo pogoste so bile spremembe v ravneh glukoze na tešče z mejnih osnovnih vrednosti (≥ 5,56 mmol/l - < 7 mmol/l) na visoke (≥ 7 mmol/l).
If you suddenly stop taking Olanzapine Teva, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. 
Če nenadno prenehate jemati zdravilo Olanzapin Teva, se lahko pojavijo simptomi, kot so znojenje,
Thromboembolis m (including pulmonary embolism and deep vein thrombosis) (see section 4.4) 
(vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje 4.4)
Olanzapine Teva 7.5 mg film-coated tablets 
Olanzapin Teva 7,5 mg filmsko obložene tablete
Excipient with known effect Each film-coated tablet contains 103.3 mg lactose. 
Ena filmsko obložena tableta vsebuje 103,3 mg laktoze.
Excipient with known effect Each film-coated tablet contains 137.8 mg lactose. 
Ena filmsko obložena tableta vsebuje 137,8 mg laktoze.
What you need to know before you take Olanzapine Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Olanzapin Teva Ne jemljite zdravila Olanzapin Teva
Following short term treatment (median duration 47 days), weight gain ≥7% of baseline body weight was very common (22.2%), ≥15% was common (4.2%) and ≥25% was uncommon (0.8%). 
S kratkoročnim zdravljenjem (srednje trajanje 47 dni) povezano zvečanje telesne mase za ≥ 7 % od osnovne telesne mase je bilo zelo pogosto (22,2 %), ≥ 15 %
Olanzapine Teva 7.5 mg film-coated tablets Each film-coated tablet contains 7.5 mg olanzapine. 
Olanzapin Teva 7,5 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 7,5 mg olanzapina.
Each Olanzapine Teva 7.5 mg film-coated tablet contains 7.5 mg of the active substance. 
Ena Olanzapin Teva 7,5 mg filmsko obložena tableta vsebuje 7,5 mg učinkovine.